Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
1. Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
(Posted: 09/17/2008) - Computerized tomographic colonography, also known as virtual colonoscopy, is comparable to standard colonoscopy, which uses a long, flexible tube with a camera to view the lining of the colon, in its ability to accurately detect cancer and precancerous polyps and could serve as an initial screening exam for colorectal cancer, according to the results of the American College of Radiology Imaging Network National CT Colonography Trial.
2. Thalidomide Effective in Multiple Myeloma
(Posted: 03/15/2006, Updated: 09/16/2008) - In the March 9, 2006, issue of the New England Journal of Medicine, researchers report superior event-free and complete response rates when the drug thalidomide was used before and during primary therapy for multiple myeloma. Longer follow-up showed a survival benefit for some patients, as well.
3. Bortezomib Approved for First-Line Treatment of Multiple Myeloma
(Posted: 09/11/2008) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), significantly improves time to progression and overall survival in patients with newly diagnosed multiple myeloma, according to the August 28, 2008, New England journal of Medicine.
4. Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
5. Eliminating a Common Bacterium Reduces Risk of Second Gastric Cancer
(Posted: 09/02/2008) - When the bacterium Helicobacter pylori is eliminated in patients who are treated for early stage gastric cancer, the risk of developing a second gastric cancer decreases by two-thirds, according to the Aug. 2, 2008, issue of The Lancet.
1 2 3 4 Next >